First Patient Dosed in Phase 2b/3 Study of TD-1473 for Ulcerative Colitis
News
Theravance Biopharma announced that the first patient has been dosed in a Phase 2b/3 study to test the efficacy and safety of its candidate oral drug TD-1473 for the treatment ... Read more